Michal Vráblík
A5086863186- Lipoproteins and Cardiovascular Health
- Cancer, Lipids, and Metabolism
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Lipid metabolism and disorders
- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical Economics and Policy
- Nutritional Studies and Diet
- Atherosclerosis and Cardiovascular Diseases
- Liver Disease Diagnosis and Treatment
- Nutrition, Genetics, and Disease
- Blood Pressure and Hypertension Studies
- Cardiac Health and Mental Health
- Diet, Metabolism, and Disease
- Estrogen and related hormone effects
- Menopause: Health Impacts and Treatments
- Peroxisome Proliferator-Activated Receptors
- Hormonal Regulation and Hypertension
- Cardiovascular Health and Disease Prevention
- Cholesterol and Lipid Metabolism
- Adipokines, Inflammation, and Metabolic Diseases
- Cardiovascular Disease and Adiposity
- Genetic Associations and Epidemiology
- Cardiac, Anesthesia and Surgical Outcomes
- Hormonal and reproductive studies
- Diabetes Treatment and Management
Charles University
2016-2025
General University Hospital in Prague
2015-2024
Masaryk University
2023
University College London
2008-2023
University Hospital Brno
2023
St. Anne's University Hospital Brno
2023
Institute of Clinical and Experimental Medicine
2023
Na Homolce Hospital
2022
Sudop Praha (Czechia)
2022
Centrum kardiovaskulární a transplantační chirurgie
2020-2022
The ESC Guidelines represent the views of and were produced after careful consideration scientific medical knowledge evidence available at time their publication.The is not responsible in event any contradiction, discrepancy, and/or ambiguity between other official recommendations or guidelines issued by relevant public health authorities, particular relation to good use healthcare therapeutic strategies.Health professionals are encouraged take fully into account when exercising clinical...
Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy bococizumab in patients at high cardiovascular risk.In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned 27,438 combined receive (at dose 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was...
Abstract Aims To provide contemporary data on the implementation of European guideline recommendations for lipid-lowering therapies (LLTs) across different settings and populations how this impacts low-density lipoprotein cholesterol (LDL-C) goal achievement. Methods results An 18 country, cross-sectional, observational study patients prescribed LLT primary or secondary prevention in care Europe. Between June 2017 November 2018, were collected at a single visit, including preceding 12 months...
1.1. Cardiovascular disease and dyslipidemia: prevalence global economic impact Cardiovascular diseases (CVDs) are the leading cause of mortality worldwide, reaching 31% deaths in 2012 [1]. In particular, atherosclerosis ischemic heart (IHD) main causes premature death Europe responsible for 42% women 38% men under 75 years old [2]. The impact CVD is estimated to have been US $906 billion 2015 expected rise by 22% 2030 [3]. also represent major disability developed countries. It has that...
Proteins play a crucial role in metabolism, maintaining fluid and acid-base balance antibody synthesis. Dietary proteins are important nutrients classified into: 1) animal (meat, fish, poultry, eggs dairy), and, 2) plant (legumes, nuts soy). modification is one of the most lifestyle changes that has been shown to significantly decrease risk cardiovascular (CV) disease (CVD) by attenuating related factors. The CVD burden reduced optimum diet through replacement unprocessed meat with low...
Atherosclerotic cardiovascular disease (ASCVD) and consequent acute coronary syndromes (ACS) are substantial contributors to morbidity mortality across Europe. Much of these diseases burden is modifiable, in particular by lipid-lowering therapy (LLT). Current guidelines based on the sound premise that with respect low density lipoprotein cholesterol (LDL-C), "lower better for longer", recent data have strongly emphasized need also "the earlier better". In addition statins, which been...
A panel of European experts on lipids and cardiovascular disease discussed clinical approaches to managing risk in practice, including residual associated with lipid abnormalities, such as atherogenic dyslipidaemia (AD). simplified definition AD was proposed enhance understanding this condition, its prevalence, impact risk. Atherogenic can be defined by high fasting triglyceride levels (≥2.3 mmol/L) low high-density lipoprotein cholesterol (HDL-c) (≤1.0 ≤1.3 mmol/L men women, respectively)...